Sorrento, NantWorks commit $20mm to new immunotherapies JV; commitments later enhanced
Sorrento Therapeutics Inc. and NantWorks LLC founder Dr. Patrick Soon-Shiong have agreed to together invest $20mm in a new joint venture, to be named The Immunotherapy Antibody JV, which will operate as an independent entity.
- Intra-Biotech Deal
- Joint Venture
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com